At Beijing GoBroad Hospital, part of the GoBroad Healthcare Group, we are redefining cancer care through science-driven innovation and a relentless focus on precision targeted therapy. As a leading research hospital in Beijing’s Changping Life Science Park, we specialize in treating challenging and critical cases, particularly solid tumors, hematologic cancers, and neurological disorders. Our mission is to bridge the gap between groundbreaking clinical research and patient-centered care, offering therapies that target cancer at its roots while minimizing harm to healthy tissues. With 500 beds, including dedicated units for early-stage clinical trials, and a team of renowned experts in cell therapy, CAR-T immunotherapy, and hematopoietic stem cell transplantation (HSCT), we deliver solutions that prioritize both survival and quality of life.

The Science Behind Precision Targeted Therapy

Precision targeted therapy begins with understanding the unique genetic and molecular profile of each patient’s cancer. At Beijing GoBroad Hospital, our Precision Diagnosis Center employs advanced molecular diagnostics, imaging, and pathology to identify specific biomarkers driving tumor growth. For example, in cases of lymphoma or myeloma, we analyze mutations like CD19 or BCMA to determine eligibility for CAR-T cell therapy. Similarly, for solid tumors such as gastrointestinal or breast cancers, we screen for targets like Claudin18.2 or HER2 to design therapies that disrupt cancer cells’ survival mechanisms. This approach allows us to pair conventional treatments like chemotherapy with precision targeted therapy, creating regimens that attack tumors more effectively while reducing side effects. Our Central Laboratory and Imaging Center support real-time monitoring, ensuring treatments adapt as the cancer evolves.

Integrating Multidisciplinary Expertise for Personalized Care

No single specialty can tackle complex cancers alone. Our Multidisciplinary Care (MDC) model unites oncologists, surgeons, immunologists, and data scientists to craft holistic plans. A patient with refractory leukemia, for instance, might receive a combination of HSCT to rebuild healthy bone marrow and CAR-T immunotherapy to eliminate residual cancer cells. For solid tumors, precision targeted therapy often involves blending minimally invasive surgery with molecularly guided drugs or radiation. Our teams also collaborate with the Data Intelligence Center to analyze treatment outcomes, refining protocols for future patients. This synergy extends to our International Patient Service Center, where we streamline care for global patients—from visa support to post-treatment follow-up—ensuring seamless access to our innovations.

Pioneering Clinical Research to Expand Treatment Horizons

As a hub for medical innovation, Beijing GoBroad Hospital drives the development of next-generation precision targeted therapies. Our Early Clinical Research Center conducts Phase I trials, testing novel drugs and therapies for safety and efficacy. For instance, we’re exploring dual-target CAR-T therapies (e.g., CD19-22 sequential CAR-T) to overcome resistance in blood cancers and expanding CAR-T applications to solid tumors like pancreatic cancer. Collaborations with biotech firms and academic institutions allow us to accelerate the translation of lab discoveries into clinical practice. Additionally, our Cardiac Safety Evaluation Center and Clinical Pharmacology team ensure that experimental treatments meet rigorous safety standards. By participating in our trials, patients gain access to cutting-edge options long before they become widely available, often turning hope into tangible progress.

Conclusion

Choosing Beijing GoBroad Hospital means partnering with a team that views precision targeted therapy as both an art and a science. From molecular diagnostics to multidisciplinary collaboration and clinical research, we tailor every step to the individual—not the disease. Whether you’re facing a relapsed hematologic cancer or a stubborn solid tumor, our expertise in CAR-T, HSCT, and biomarker-driven treatments offers a path forward. Explore how GoBroad Healthcare Group’s fusion of innovation and compassion can redefine your cancer journey. Here, we don’t just treat illness; we engineer possibilities.